Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma

Breast Cancer Research and Treatment

Volumn 88, Issue 2, 2004, Pages 141-148

  Yen, Wan Ching ^a   Prudente, Rene Y ^a   Lamph, William W ^a  

^a LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

bexarotene; drug synergy; mammary carcinoma; paclitaxel; retinoid X receptor

Indexed keywords

BEXAROTENE; PACLITAXEL; RETINOID X RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CELL DEATH; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DEATH; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; PACLITAXEL; RATS; TETRAHYDRONAPHTHALENES; TUMOR CELLS, CULTURED;

EID: 9644295744     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-004-1426-5     Document Type: Article

References (20)

1. Harn SM, Liebman JE, Cook J, Fisher J, Goldspiel B, Venzon D, Mitchell JB, Kaufman D: Taxol in combination with doxorubicin or etoposide. Cancer 72: 2705-2711, 1993
2. Tolcher AW: Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer. Semin Oncol 23 (Suppl 1): 37-43, 1996
3. Fornier M, Esteva FJ, Seidman AD: Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. Semin Oncol 27 (6 Suppl 11): 38-45, 2000
4. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP: Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 15: 55-61, 1993
5. Sangrajrang S, Fellous A: Taxol Resistance. Chemotherapy 46: 327-334, 2000
6. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805, 1991
7. Boehm MF, Zhang L, Badea BA, White SK, Mais DE, Berger E, Suto CM, Goldman ME, Heyman RA: Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J Med Chem 37: 2930-2941, 1994
8. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA: Chemprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 56: 5566-5570, 1996
9. Wu K, Zhang Y, Xu X-C, Hill J, Celestino J, Kim H-T, Mohsin SK, Hilsenbeck SG, Lamph WW, Bissonnette R, Brown PH: The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res 62: 6376-6380, 2002
10. Wu K, Kim H-T, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu X-C, Lamph WW, Kuhn JG, Green JE, Brown PH: Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epid Biomarker Prevention 11: 467-474, 2003
11. Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW: Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (Targretin) causes complete regression of mammary carcinoma. Cancer Res. 58: 479-484, 1998
12. Bischoff ED, Heyman RA, Lamph WW: Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure. J Natl Cancer Inst 91: 2118-2123, 1999
13. Agarwal VR, Bischoff ED. Hermann T, Lamph WW: Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand LGD1069 (Targretin). Cancer Res 60: 6033-6038, 2000
14. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, Crowley C, Yocum RC: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trail results. J Clin Oncology 19: 2456-2471, 2001
15. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984
16. Chou TC: The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TC, Rideout DC (eds) Synergism and Antagonism in Chemotherapy. Academic Press, NY, 1991, pp 61-102
17. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Nechers LM: Taxol-induced apoptosis and phosphorylation of bcl-2 protein involves c-raf-1 and represents a novel c-raf-1 signal transduction pathway. Cancer Res. 56: 1851-1854, 1996
18. 2-terminal kinase (JNK/SAPK). J Biol Chem 273: 28253-28260, 1998
19. Vivat-hannah V, You D, Rizzo C, Daris J-P, Lapointe P, Zusi C, Marinier A, Lorenzi MV, Gottardis MM: Synergistic cytotoxicity exhibited by combination treatment of selective retinoid ligands with Taxol (paclitaxel). Cancer Res 61: 8703-8711, 2001
20. Yen A, Roberson MS, Varvayanis S, Lee AT: Retinoic acid induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MAT kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Cancer Res 58: 3163-3172, 1998